Neopharm Group Overview
Neopharm is a family of companies that engage in the research and development, manufacturing, marketing, sales, and distribution of a broad range of products in the healthcare market in more than 60 countries worldwide. The Neopharm Group operates in three major segments: pharmaceutical, consumer healthcare, and medical devices.
Latest News
growth-positive
Amylyx and Neopharm sign licence agreement for ALS therapy
Amylyx Pharmaceuticals has signed a license and distribution agreement with Neopharm to commercialize AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). Neopharm will have exclusive rights to commercialize the therapy in Israel, West Bank, Gaza, and the Palestinian Authority. The agreement will help expand the availability of AMX0035 in the EMEA region if approved. AMX0035 has already received approval in the US and Canada, and the European Medicines Agency is reviewing its application for approval in Europe. The partnership with Neopharm will aid in reaching eligible ALS patients more quickly and efficiently.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Mature |
| Rounds | 0 |
| Investors | 0 |
Team Members
4
Employees: 51-200
Web & Social Links
| Website | neopharmgroup.com |
Locations
HaShiloah St 6, Petah Tikva, Israel
Photos & Videos
No files yet
